{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:46:35Z","timestamp":1768002395470,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-024-04862-0","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T16:02:03Z","timestamp":1710604923000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment intensification strategies for men undergoing definitive radiotherapy for high-risk prostate cancer"],"prefix":"10.1007","volume":"42","author":[{"given":"John","family":"Nikitas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amar","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai","family":"Duriseti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas G.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Rettig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne","family":"Brisbane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-4174","authenticated-orcid":false,"given":"Luca","family":"Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,16]]},"reference":[{"issue":"1","key":"4862_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/CAAC.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7\u201333. https:\/\/doi.org\/10.3322\/CAAC.21708","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4862_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/S00345-008-0250-7","volume":"26","author":"MR Cooperberg","year":"2008","unstructured":"Cooperberg MR, Cowan J, Broering JM, Carroll PR (2008) High-risk prostate cancer in the United States, 1990\u20132007. World J Urol 26(3):211\u2013218. https:\/\/doi.org\/10.1007\/S00345-008-0250-7","journal-title":"World J Urol"},{"key":"4862_CR3","doi-asserted-by":"publisher","unstructured":"Nezolosky M, Nguyen PL, Yang DD (2018) Which patients with localized prostate cancer account for the greatest proportion of prostate cancer deaths? JCO 36(6_suppl):130 https:\/\/doi.org\/10.1200\/JCO.2018.36.6_SUPPL.130","DOI":"10.1200\/JCO.2018.36.6_SUPPL.130"},{"issue":"10","key":"4862_CR4","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/J.CLON.2014.06.016","volume":"26","author":"M Schmidt-Hansen","year":"2014","unstructured":"Schmidt-Hansen M, Hoskin P, Kirkbride P, Hasler E, Bromham N (2014) Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: a systematic review with meta-analyses. Clin Oncol (R Coll Radiol) 26(10):e21\u2013e46. https:\/\/doi.org\/10.1016\/J.CLON.2014.06.016","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"2","key":"4862_CR5","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","volume":"23","author":"AU Kishan","year":"2022","unstructured":"Kishan AU, Sun Y, Hartman H et al (2022) Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol 23(2):304\u2013316. https:\/\/doi.org\/10.1016\/S1470-2045(21)00705-1","journal-title":"Lancet Oncol"},{"issue":"11","key":"4862_CR6","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","volume":"11","author":"M Bolla","year":"2010","unstructured":"Bolla M, Van Tienhoven G, Warde P et al (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11(11):1066\u20131073. https:\/\/doi.org\/10.1016\/S1470-2045(10)70223-0","journal-title":"Lancet Oncol"},{"issue":"5","key":"4862_CR7","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/J.IJROBP.2004.08.047","volume":"61","author":"MV Pilepich","year":"2005","unstructured":"Pilepich MV, Winter K, Lawton CA et al (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma\u2014long-term results of phase III RTOG 85\u201331. Int J Radiat Oncol Biol Phys 61(5):1285\u20131290. https:\/\/doi.org\/10.1016\/J.IJROBP.2004.08.047","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"4862_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/NRUROL.2015.50","volume":"12","author":"JA Locke","year":"2015","unstructured":"Locke JA, Pra AD, Supiot S, Warde P, Bristow RG (2015) Synergistic action of image-guided radiotherapy and androgen deprivation therapy. Nat Rev Urol 12(4):193\u2013204. https:\/\/doi.org\/10.1038\/NRUROL.2015.50","journal-title":"Nat Rev Urol"},{"issue":"5","key":"4862_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/J.EURURO.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen PL, Alibhai SMH, Basaria S et al (2015) Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67(5):825\u2013836. https:\/\/doi.org\/10.1016\/J.EURURO.2014.07.010","journal-title":"Eur Urol"},{"issue":"24","key":"4862_CR10","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1056\/NEJMOA0810095","volume":"360","author":"M Bolla","year":"2009","unstructured":"Bolla M, de Reijke TM, Van Tienhoven G et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516\u20132527. https:\/\/doi.org\/10.1056\/NEJMOA0810095","journal-title":"N Engl J Med"},{"issue":"2","key":"4862_CR11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/J.IJROBP.2017.02.004","volume":"98","author":"CAF Lawton","year":"2017","unstructured":"Lawton CAF, Lin X, Hanks GE et al (2017) Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG oncology RTOG 9202. Int J Radiat Oncol Biol Phys 98(2):296\u2013303. https:\/\/doi.org\/10.1016\/J.IJROBP.2017.02.004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4862_CR12","doi-asserted-by":"publisher","unstructured":"Zapatero A et al (2015) High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01\/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol 16(3):320\u2013327. https:\/\/doi.org\/10.1016\/S1470-2045(15)70045-8","DOI":"10.1016\/S1470-2045(15)70045-8"},{"issue":"5","key":"4862_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(22)00190-5","volume":"23","author":"A Zapatero","year":"2022","unstructured":"Zapatero A, Guerrero A, Maldonado X et al (2022) High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01\/05): 10-year results of a phase 3 randomised, controlled trial. Lancet Oncol 23(5):671\u2013681. https:\/\/doi.org\/10.1016\/S1470-2045(22)00190-5","journal-title":"Lancet Oncol"},{"key":"4862_CR14","doi-asserted-by":"publisher","unstructured":"Denham JW, Joseph D, Lamb DS et al. (2019) Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. Lancet Oncol 20(2):267\u2013281. https:\/\/doi.org\/10.1016\/S1470-2045(18)30757-5","DOI":"10.1016\/S1470-2045(18)30757-5"},{"issue":"4","key":"4862_CR15","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/J.EURURO.2018.06.018","volume":"74","author":"A Nabid","year":"2018","unstructured":"Nabid A, Carrier N, Martin AG et al (2018) Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial. Eur Urol 74(4):432\u2013441. https:\/\/doi.org\/10.1016\/J.EURURO.2018.06.018","journal-title":"Eur Urol"},{"issue":"4","key":"4862_CR16","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/0360-3016(94)90563-0","volume":"29","author":"MJ Zelefsky","year":"1994","unstructured":"Zelefsky MJ, Leibel SA, Burman CM et al (1994) Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 29(4):755\u2013761. https:\/\/doi.org\/10.1016\/0360-3016(94)90563-0","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"4862_CR17","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1007\/S00330-015-3688-1\/TABLES\/5","volume":"25","author":"AM H\u00f6tker","year":"2015","unstructured":"H\u00f6tker AM, Mazaheri Y, Zheng J et al (2015) Prostate cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI. Eur Radiol 25(9):2665\u20132672. https:\/\/doi.org\/10.1007\/S00330-015-3688-1\/TABLES\/5","journal-title":"Eur Radiol"},{"key":"4862_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.clon.2012.09.010","volume":"25","author":"M Mason","year":"2013","unstructured":"Mason M, Maldonado Pijoan X, Steidle C et al (2013) Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of Degarelix versus Goserelin plus Bicalutamide. Clin Oncol 25:190\u2013196. https:\/\/doi.org\/10.1016\/j.clon.2012.09.010","journal-title":"Clin Oncol"},{"key":"4862_CR19","doi-asserted-by":"publisher","unstructured":"Rice MA, Malhotra SV, Stoyanova T (2019) Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer. Front Oncol 9:801. https:\/\/doi.org\/10.3389\/FONC.2019.00801","DOI":"10.3389\/FONC.2019.00801"},{"issue":"12","key":"4862_CR20","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1634\/THEONCOLOGIST.2014-0167","volume":"19","author":"RJ Auchus","year":"2014","unstructured":"Auchus RJ, Yu MK, Nguyen S, Mundle SD (2014) Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. Oncologist 19(12):1231. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2014-0167","journal-title":"Oncologist"},{"key":"4862_CR21","unstructured":"Goldberg T, Berrios-Colon E. Abiraterone (Zytiga), a novel agent for the management of castration-resistant prostate cancer. Pharm Ther 38(1):23. \/pmc\/articles\/PMC3628169\/. Accessed 9 July 2023"},{"key":"4862_CR22","doi-asserted-by":"publisher","unstructured":"Rajaram P, Rivera A, Muthima K, Olveda N, Muchalski H, Chen QH (2020) Second-generation androgen receptor antagonists as hormonal therapeutics for three forms of prostate cancer. Molecules 25(10):2448. https:\/\/doi.org\/10.3390\/MOLECULES25102448","DOI":"10.3390\/MOLECULES25102448"},{"issue":"4","key":"4862_CR23","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMOA1704174\/SUPPL_FILE\/NEJMOA1704174_DISCLOSURES.PDF","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus Prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352\u2013360. https:\/\/doi.org\/10.1056\/NEJMOA1704174\/SUPPL_FILE\/NEJMOA1704174_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"issue":"2","key":"4862_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMOA1903835\/SUPPL_FILE\/NEJMOA1903835_DATA-SHARING.PDF","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR et al (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381(2):121\u2013131. https:\/\/doi.org\/10.1056\/NEJMOA1903835\/SUPPL_FILE\/NEJMOA1903835_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"issue":"32","key":"4862_CR25","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP et al (2019) Arches: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 37(32):2974\u20132986. https:\/\/doi.org\/10.1200\/JCO.19.00799","journal-title":"J Clin Oncol"},{"issue":"10323","key":"4862_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW et al (2022) Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 399(10323):447\u2013460. https:\/\/doi.org\/10.1016\/S0140-6736(21)02437-5","journal-title":"Lancet"},{"key":"4862_CR27","doi-asserted-by":"publisher","unstructured":"Spratt DE, Sun Y, Van der Wal D et al (2022) An AI-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy in localized prostate cancer with validation in NRG\/RTOG 9408. JCO 40(6_suppl):223\u2013223. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_SUPPL.223","DOI":"10.1200\/JCO.2022.40.6_SUPPL.223"},{"key":"4862_CR28","doi-asserted-by":"publisher","unstructured":"Oh J, Tyldesley S, Pai H et al (2023) An updated analysis of the survival endpoints of ASCENDE-RT. Int J Radiat Oncol Biol Phys 115(5):1061\u20131070. https:\/\/doi.org\/10.1016\/J.IJROBP.2022.11.005","DOI":"10.1016\/J.IJROBP.2022.11.005"},{"issue":"2","key":"4862_CR29","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/J.IJROBP.2017.01.008","volume":"98","author":"S Rodda","year":"2017","unstructured":"Rodda S, Tyldesley S, Morris WJ et al (2017) ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 98(2):286\u2013295. https:\/\/doi.org\/10.1016\/J.IJROBP.2017.01.008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"4862_CR30","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1001\/JAMA.2018.0587","volume":"319","author":"AU Kishan","year":"2018","unstructured":"Kishan AU, Cook RR, Ciezki JP et al (2018) Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9\u201310 prostate cancer. JAMA 319(9):896. https:\/\/doi.org\/10.1001\/JAMA.2018.0587","journal-title":"JAMA"},{"key":"4862_CR31","doi-asserted-by":"publisher","unstructured":"Joseph D, Denham JW, Steigler A et al (2020) Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-year data from the TROG 03.04 RADAR trial. Int J Radiat Oncol Biol Phys 106(4):693\u2013702. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.11.415","DOI":"10.1016\/j.ijrobp.2019.11.415"},{"issue":"7","key":"4862_CR32","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.20.02873","volume":"39","author":"LGW Kerkmeijer","year":"2021","unstructured":"Kerkmeijer LGW, Groen VH, Pos FJ et al (2021) Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol 39(7):787\u2013796. https:\/\/doi.org\/10.1200\/JCO.20.02873","journal-title":"J Clin Oncol"},{"issue":"2","key":"4862_CR33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/J.IJROBP.2022.09.058","volume":"115","author":"AC Tree","year":"2023","unstructured":"Tree AC, Satchwell L, Alexander E et al (2023) Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: 5-year efficacy and toxicity in the DELINEATE trial. Int J Radiat Oncol Biol Phys 115(2):305\u2013316. https:\/\/doi.org\/10.1016\/J.IJROBP.2022.09.058","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"4862_CR34","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1200\/JCO.20.03282","volume":"39","author":"V Murthy","year":"2021","unstructured":"Murthy V, Maitre P, Kannan S et al (2021) Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol 39(11):1234\u20131242. https:\/\/doi.org\/10.1200\/JCO.20.03282","journal-title":"J Clin Oncol"},{"issue":"4","key":"4862_CR35","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/J.IJROBP.2016.06.2455","volume":"96","author":"P Pommier","year":"2016","unstructured":"Pommier P, Chabaud S, Lagrange JL et al (2016) Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. Int J Radiat Oncol Biol Phys 96(4):759\u2013769. https:\/\/doi.org\/10.1016\/J.IJROBP.2016.06.2455","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"4862_CR36","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","volume":"19","author":"M Roach","year":"2018","unstructured":"Roach M, Moughan J, Lawton CAF et al (2018) Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol 19(11):1504\u20131515. https:\/\/doi.org\/10.1016\/S1470-2045(18)30528-X","journal-title":"Lancet Oncol"},{"issue":"6","key":"4862_CR37","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/0360-3016(88)90225-8","volume":"15","author":"SO Asbell","year":"1988","unstructured":"Asbell SO, Krall JM, Pilepich MV et al (1988) Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77\u201306. Int J Radiat Oncol Biol Phys 15(6):1307\u20131316. https:\/\/doi.org\/10.1016\/0360-3016(88)90225-8","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04862-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-04862-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04862-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:23:43Z","timestamp":1735853023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-04862-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,16]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4862"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-04862-0","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,16]]},"assertion":[{"value":"2 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"165"}}